Published in Cancer Res on August 01, 2008
Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. Breast Cancer Res Treat (2011) 1.96
Systems biology and genomics of breast cancer. Cold Spring Harb Perspect Biol (2011) 1.59
INCORPORATING BIOLOGICAL INFORMATION INTO LINEAR MODELS: A BAYESIAN APPROACH TO THE SELECTION OF PATHWAYS AND GENES. Ann Appl Stat (2011) 1.42
Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss. Genes Dev (2015) 1.27
Integrative network analysis reveals active microRNAs and their functions in gastric cancer. BMC Syst Biol (2011) 1.17
Estrogen receptor silencing induces epithelial to mesenchymal transition in human breast cancer cells. PLoS One (2011) 1.09
Retrospective analysis of metastatic behaviour of breast cancer subtypes. Breast Cancer Res Treat (2015) 1.01
Confounding effects in "A six-gene signature predicting breast cancer lung metastasis". Cancer Res (2009) 0.99
Ceramide glycosylation catalyzed by glucosylceramide synthase and cancer drug resistance. Adv Cancer Res (2013) 0.99
αvβ8 integrin interacts with RhoGDI1 to regulate Rac1 and Cdc42 activation and drive glioblastoma cell invasion. Mol Biol Cell (2013) 0.97
Biological convergence of cancer signatures. PLoS One (2009) 0.97
Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat (2012) 0.94
The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis. Mol Cancer (2014) 0.93
Novel genes associated with lymph node metastasis in triple negative breast cancer. Sci Rep (2015) 0.92
Microenvironmental Influences on Metastasis Suppressor Expression and Function during a Metastatic Cell's Journey. Cancer Microenviron (2014) 0.92
Translational disease interpretation with molecular networks. Genome Biol (2009) 0.91
Specific genomic aberrations in primary colorectal cancer are associated with liver metastases. BMC Cancer (2010) 0.89
Expression profiles of podocytes exposed to high glucose reveal new insights into early diabetic glomerulopathy. Lab Invest (2010) 0.88
Development of multigene expression signature maps at the protein level from digitized immunohistochemistry slides. PLoS One (2012) 0.88
Analysis of a bone metastasis gene expression signature in patients with bone metastasis from solid tumors. Clin Exp Metastasis (2011) 0.87
A common variant of the MACC1 gene is significantly associated with overall survival in colorectal cancer patients. BMC Cancer (2012) 0.87
Expression of endoplasmic reticulum stress proteins is a candidate marker of brain metastasis in both ErbB-2+ and ErbB-2- primary breast tumors. Am J Pathol (2011) 0.85
Ceramide galactosyltransferase (UGT8) is a molecular marker of breast cancer malignancy and lung metastases. Br J Cancer (2010) 0.84
Feasibility of using gene expression analysis to study canine soft tissue sarcomas. Mamm Genome (2010) 0.83
Biological resonance for cancer metastasis, a new hypothesis based on comparisons between primary cancers and metastases. Cancer Microenviron (2013) 0.82
The tumour-promoting receptor tyrosine kinase, EphB4, regulates expression of integrin-β8 in prostate cancer cells. BMC Cancer (2015) 0.81
Data reporting standards: making the things we use better. Genome Med (2009) 0.80
Galactosylceramide affects tumorigenic and metastatic properties of breast cancer cells as an anti-apoptotic molecule. PLoS One (2013) 0.80
Systematic analysis of metastasis-associated genes identifies miR-17-5p as a metastatic suppressor of basal-like breast cancer. Breast Cancer Res Treat (2014) 0.79
Lymphangioleiomyomatosis Biomarkers Linked to Lung Metastatic Potential and Cell Stemness. PLoS One (2015) 0.79
Gene expression in "young adult type" breast cancer: a retrospective analysis. Oncotarget (2015) 0.79
The inhibitor of kappa B kinase-epsilon regulates MMP-3 expression levels and can promote lung metastasis. Oncogenesis (2014) 0.78
A computational model to predict bone metastasis in breast cancer by integrating the dysregulated pathways. BMC Cancer (2014) 0.77
A novel gene expression signature for bone metastasis in breast carcinomas. Breast Cancer Res Treat (2016) 0.77
FN14 and GRP94 expression are prognostic/predictive biomarkers of brain metastasis outcome that open up new therapeutic strategies. Oncotarget (2015) 0.76
Confounding effects in "a six-gene signature predicting breast cancer lung metastasis": reply. Cancer Res (2009) 0.76
The role of the cell-cell interactions in cancer progression. J Cell Mol Med (2015) 0.75
Site-dependent differences in clinical, pathohistological, and molecular parameters in metastatic colon cancer. Int J Biol Sci (2009) 0.75
Differentially correlated genes in co-expression networks control phenotype transitions. F1000Res (2016) 0.75
Downregulation of miRNA-141 in breast cancer cells is associated with cell migration and invasion: involvement of ANP32E targeting. Cancer Med (2017) 0.75
A 3q gene signature associated with triple negative breast cancer organ specific metastasis and response to neoadjuvant chemotherapy. Sci Rep (2017) 0.75
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res (2007) 8.41
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst (2006) 8.38
Effect of artemether-lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa. PLoS Med (2005) 8.36
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 6.73
Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell (2010) 5.08
Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA (2011) 4.84
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature (2011) 3.53
Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer (2008) 3.04
The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev (2007) 2.96
Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther (2002) 2.83
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res (2006) 2.76
ANRIL, a long, noncoding RNA, is an unexpected major hotspot in GWAS. FASEB J (2010) 2.73
Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ (2012) 2.44
Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. Clin Cancer Res (2003) 2.37
Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene (2002) 2.32
Genetics, pathogenesis and complications of osteopetrosis. Bone (2007) 2.25
Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). J Natl Cancer Inst (2006) 2.25
Organized proteomic heterogeneity in colorectal cancer liver metastases and implications for therapies. Hepatology (2013) 2.10
Inhibitory signalling to the Arp2/3 complex steers cell migration. Nature (2013) 2.06
Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. Endocr Relat Cancer (2006) 2.04
Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet (2007) 2.04
Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene (2002) 2.02
SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer (2007) 2.01
Comments on the use of a single or multiple probeset approach for microarray-based analyses of routine molecular markers in breast cancer. Breast Cancer Res Treat (2012) 1.97
IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol (2011) 1.97
Prognostic value of ERBB family mRNA expression in breast carcinomas. Int J Cancer (2003) 1.95
Experimental anti-angiogenesis causes upregulation of genes associated with poor survival in glioblastoma. Int J Cancer (2008) 1.93
Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. Clin Cancer Res (2003) 1.84
Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J Clin Oncol (2007) 1.83
NF-kappa B genes have a major role in inflammatory breast cancer. BMC Cancer (2008) 1.82
[Identification and management of hereditary predisposition to cancer of the breast and the ovary (update 2004)]. Bull Cancer (2004) 1.80
Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on BRCA1 and BRCA2 variants. Hum Mutat (2012) 1.77
Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature. Clin Cancer Res (2004) 1.77
Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Mol Cancer (2008) 1.72
Histone deacetylase HDAC8 associates with smooth muscle alpha-actin and is essential for smooth muscle cell contractility. FASEB J (2005) 1.70
Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers. EMBO Mol Med (2011) 1.68
Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer. JAMA (2005) 1.68
The forkhead transcription factor AFX activates apoptosis by induction of the BCL-6 transcriptional repressor. J Biol Chem (2002) 1.68
Splicing switch of an epigenetic regulator by RNA helicases promotes tumor-cell invasiveness. Nat Struct Mol Biol (2012) 1.67
Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Res (2007) 1.63
CXC chemokines located in the 4q21 region are up-regulated in breast cancer. Endocr Relat Cancer (2007) 1.62
Professionals assess the acceptability of preimplantation genetic diagnosis and prenatal diagnosis for managing inherited predisposition to cancer. J Clin Oncol (2009) 1.62
High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res (2009) 1.61
Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet Genomics (2007) 1.59
Gene array analysis of Wnt-regulated genes in C3H10T1/2 cells. Bone (2005) 1.55
Chloride channel ClCN7 mutations are responsible for severe recessive, dominant, and intermediate osteopetrosis. J Bone Miner Res (2003) 1.55
Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells. Prostate (2012) 1.54
TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma. Cancer Cell (2004) 1.54
Impaired gastric acidification negatively affects calcium homeostasis and bone mass. Nat Med (2009) 1.52
Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. Gastroenterology (2005) 1.48
Overexpression of the homeobox gene HOXC8 in human prostate cancer correlates with loss of tumor differentiation. Prostate (2002) 1.48
Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas. Oncogene (2004) 1.48
Hiccup in patients with advanced cancer successfully treated with gabapentin: report of three cases. N Z Med J (2003) 1.47
PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups. Breast Cancer Res (2012) 1.47
NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype. Hum Mutat (2010) 1.47
Histone deacetylase 7 silencing alters endothelial cell migration, a key step in angiogenesis. Circ Res (2007) 1.46
Kinase-dependent and -independent roles of EphA2 in the regulation of prostate cancer invasion and metastasis. Am J Pathol (2009) 1.46
Histone deacetylase 4 is required for TGFbeta1-induced myofibroblastic differentiation. Biochim Biophys Acta (2007) 1.43
In vivo hepatic endoplasmic reticulum stress in patients with chronic hepatitis C. J Pathol (2010) 1.41
Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2010) 1.41
microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer. Int J Cancer (2013) 1.40
Elevated growth-arrest-specific protein 6 plasma levels in patients with severe sepsis. Crit Care Med (2006) 1.37
Galectin-3 and cancer (Review). Int J Oncol (2004) 1.37
Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev (2007) 1.36
Histone deacetylases: target enzymes for cancer therapy. Clin Exp Metastasis (2007) 1.35
Expression of platelet-derived growth factor-A (PDGF-A), PDGF-B, and PDGF receptor-alpha and -beta during human testicular development and disease. J Clin Endocrinol Metab (2002) 1.34
Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum (2006) 1.31
Alternative transcripts of the candidate tumor suppressor gene, WWOX, are expressed at high levels in human breast tumors. Oncogene (2002) 1.31
Involvement of PLEKHM1 in osteoclastic vesicular transport and osteopetrosis in incisors absent rats and humans. J Clin Invest (2007) 1.29
Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol (2013) 1.29
Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations. Eur J Hum Genet (2004) 1.29
Update on inflammatory breast cancer. Breast Cancer Res (2005) 1.29
Expression of galectins in cancer: a critical review. Glycoconj J (2004) 1.28
SWI/SNF chromatin remodeling and human malignancies. Annu Rev Pathol (2014) 1.27
Telangiectatic focal nodular hyperplasia: a variant of hepatocellular adenoma. Gastroenterology (2004) 1.26
Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy. J Pharmacol Exp Ther (2006) 1.26
Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3. Oncogene (2004) 1.26
CD133, CD15/SSEA-1, CD34 or side populations do not resume tumor-initiating properties of long-term cultured cancer stem cells from human malignant glio-neuronal tumors. BMC Cancer (2010) 1.26
Radiation dose and risk of soft tissue and bone sarcoma after breast cancer treatment. Breast Cancer Res Treat (2005) 1.25